Frontiers in Oncology (Jun 2024)

Spotlight on borderline-IGHV mutational status in chronic lymphocytic leukemia

  • Souraya Rammal,
  • Warde Semaan,
  • Natalia Aprahamian,
  • Romy Moussallem,
  • Alain Chebly,
  • Alain Chebly

DOI
https://doi.org/10.3389/fonc.2024.1430225
Journal volume & issue
Vol. 14

Abstract

Read online

Mutated or unmutated immunoglobulin heavy chain (IGHV) gene is an important prognostic factor in chronic lymphocytic leukemia (CLL). However, a small fraction of patients with CLL are classified as borderline (BL)-IGHV. Few data are available on this subgroup of CLL. In this paper, we retrospectively report and analyze data from 21 patients with BL-IGHV CLL, showing the heterogeneity of this subgroup of CLL and paving the way for more research focusing on this entity to optimize the management and treatment of patients with Borderline-IGHV CLL.

Keywords